Recognizing the high cost of chemotherapy drugs, and the increasing health care expenses of adult leukemia patients, EPCALM, under its Medical Service Arm, assisted serviced patients through the provision of prescribed oral chemotherapy drugs and maintenance medicines in 2022.
The cancer medicines were released in two batches, after prior screening and submission of prescriptions issued by the patients’ respective oncologists. In July 2022, oral chemotherapy drugs were received by 14 patients. Seven patients were provided with Tasigna (Nilotinib), while seven patients were given Imatinib. Meanwhile, three other patients were provided with their maintenance medicines. In December 2022, eight patients were supported, for a total of 25 patients for both batches.
The Medical Service Arm seeks to provide adult leukemia patients with guided options for the best medical care, and direct them to appropriate centers for treatment – locally, nationally or internationally.
Comments